Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Combination Gene and Stem Cell Therapy Cures Muscular Dystrophy in Mouse Model

By BiotechDaily International staff writers
Posted on 19 Mar 2013
In a "proof-of-principle" study, researchers have shown that it was possible to cure Duchenne Muscular Dystrophy (DMD) in a mouse model using a combination of gene and stem cell therapy.

Investigators at the University of Minnesota (Minneapolis, USA) began by reprogramming skin cells taken from DMD mice back into an undifferentiated pluripotent stem cell stage. They then employed a gene therapy approach based on the "Sleeping Beauty Transposon" to incorporate the gene for the protein utrophin into the stem cells. Utrophin can substitute for the defective protein dystrophin, which characterizes DMD, without generating an autoimmune response.

The last step was to treat the modified pluripotent cells with the muscle stem cell protein Pax3 (paired box 3), which induced the stem cells to differentiate into muscle cells. Pax3 is expressed in early embryonic growth where it helps to demarcate the paraxial mesoderm. In that way, PAX3 contributes to early striated muscle development since all myoblasts are derived from the paraxial mesoderm.

The modified stem cells were injected into DMD mice. Results published in the March 5, 2013, online edition of the journal Nature Communications revealed that the stem cells were incorporated into muscle tissue that displayed large numbers of micro-utrophin-positive myofibers, with biochemically restored dystrophin–glycoprotein complexes, and improved contractile strength.

"Developing methods to genetically repair muscular dystrophy in human cells, and demonstrating efficacy of muscle derived from these cells are critical near-term milestones, both for the field and for our laboratory," said senior author Dr. Rita Perlingeiro, associate professor of medicine at the University of Minnesota. "Testing in animal models is essential to developing effective technologies, but we remained focused on bringing these technologies into use in human cells and setting the stage for trials in human patients."

"We were pleased to find the newly formed myofibers expressed the markers of the correction, including utrophin," said, Dr. Perlingeiro. "However, a very important question following transplantation is if these corrected cells would self-renew, and produce new muscle stem cells in addition to the new muscle fibers."

Related Links:

University of Minnesota



RANDOX LABORATORIES
BIOSIGMA S.R.L.
SLAS - Society for Laboratory Automation and Screening
comments powered by Disqus

Channels

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: On target: When researchers introduced nanobodies they made to cells engineered to express a tagged version of a protein in skeletal fibers known as tubulin (red), the nanobodies latched on. The cells above have recently divided (Photo courtesy of Rockefeller University).

Turning Antibodies into Precisely Tuned Nanobodies

New technology has the potential to create nanobodies making them much more accessible than antibodies for all sorts of research. Antibodies control the process of recognizing and zooming in on molecular... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.